Orphazyme Valuation
| ORPHA Stock | DKK 980.00 39.00 3.83% |
At this time, the company appears to be overvalued. Orphazyme AS holds a recent Real Value of kr855.79 per share. The prevailing price of the company is kr980.0. Our model determines the value of Orphazyme AS from analyzing the company fundamentals such as Return On Equity of -4.87, shares outstanding of 35.31 M, and Operating Margin of (15.38) % as well as examining its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Orphazyme's price fluctuation is very steady at this time. Calculation of the real value of Orphazyme AS is based on 3 months time horizon. Increasing Orphazyme's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Orphazyme is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Orphazyme Stock. However, Orphazyme's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 980.0 | Real 855.79 | Hype 980.0 | Naive 954.34 |
The real value of Orphazyme Stock, also known as its intrinsic value, is the underlying worth of Orphazyme AS Company, which is reflected in its stock price. It is based on Orphazyme's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Orphazyme's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Orphazyme AS helps investors to forecast how Orphazyme stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Orphazyme more accurately as focusing exclusively on Orphazyme's fundamentals will not take into account other important factors: Orphazyme Total Value Analysis
Orphazyme AS is now forecasted to have takeover price of (12.81 M) with market capitalization of 30.82 M, debt of 2.48 M, and cash on hands of 726.93 M. The negative valuation of Orphazyme may imply that the market is not capable to price the future growth of the company or it is pricing it at zero value. It may also suggest that takeover valuation may not have captured all of the outstanding financial obligations of the company both on and off balance sheet. Investors should thoroughly investigate all of the Orphazyme fundamentals.| Takeover Price | Market Cap | Debt Obligations | Cash |
(12.81 M) | 30.82 M | 2.48 M | 726.93 M |
Orphazyme Investor Information
The company has price-to-book ratio of 0.47. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Orphazyme AS recorded a loss per share of 17.94. The entity had not issued any dividends in recent years. The firm had 1000:1 split on the 5th of December 2023. Based on the measurements of operating efficiency obtained from Orphazyme's historical financial statements, Orphazyme AS is not in a good financial situation at the moment. It has a very high risk of going through financial straits in January.Orphazyme Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Orphazyme has an asset utilization ratio of 20.89 percent. This indicates that the Company is making kr0.21 for each dollar of assets. An increasing asset utilization means that Orphazyme AS is more efficient with each dollar of assets it utilizes for everyday operations.Orphazyme Ownership Allocation
Orphazyme owns a total of 35.31 Million outstanding shares. Roughly 90.51 pct. of Orphazyme outstanding shares are held by general public with 1.36 % owned by insiders and only 8.13 (%) by third-party entities. Please note that no matter how many assets the company maintains, if the real value of the company is less than the current market value, you may not be able to make money on it.Orphazyme Profitability Analysis
The company reported the revenue of 36.19 M. Net Loss for the year was (626.54 M) with profit before overhead, payroll, taxes, and interest of 36.19 M.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Orphazyme's worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Orphazyme and how it compares across the competition.
About Orphazyme Valuation
The stock valuation mechanism determines Orphazyme's current worth on a weekly basis. Our valuation model uses a comparative analysis of Orphazyme. We calculate exposure to Orphazyme's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Orphazyme's related companies.Orphazyme AS, a biopharmaceutical company, develops therapies for the treatment of neurodegenerative orphan diseases. The company was incorporated in 2009 and is headquartered in Copenhagen, Denmark. Orphazyme is traded on Copenhagen Stock Exchange in Denmark.
8 Steps to conduct Orphazyme's Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates Orphazyme's potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Orphazyme's valuation analysis, follow these 8 steps:- Gather financial information: Obtain Orphazyme's financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Orphazyme's revenue streams: Identify Orphazyme's primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Orphazyme's industry and market trends, including the size of the market, growth rate, and competition.
- Establish Orphazyme's growth potential: Evaluate Orphazyme's management, business model, and growth potential.
- Determine Orphazyme's financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Orphazyme's estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Complementary Tools for Orphazyme Stock analysis
When running Orphazyme's price analysis, check to measure Orphazyme's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Orphazyme is operating at the current time. Most of Orphazyme's value examination focuses on studying past and present price action to predict the probability of Orphazyme's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Orphazyme's price. Additionally, you may evaluate how the addition of Orphazyme to your portfolios can decrease your overall portfolio volatility.
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas |